TABLE 1.
Antiviral activity of representative compounds against wild-type and mutant HBV
| Compound | Mean EC50 ± SD (μM) against HBV with indicated mutation(s)a |
||||||
|---|---|---|---|---|---|---|---|
| None (WT) | F97L | V124A | V124F | V124W | WT+V124F | VT+V124W | |
| Bay 41-4109 | 0.09 ± 0.01 | 0.13 ± 0.01 | 0.08 ± 0.02 | >2.00 | >2.00 | 0.09 ± 0.02 | 0.91 ± 0.09 |
| BA-38017 | 0.24 ± 0.01 | 0.67 ± 0.03 | 0.92 ± 0.13 | 0.23 ± 0.02 | 3.10 ± 1.07 | 0.47 ± 0.02 | 0.66 ± 0.10 |
| ENAN-34017 | 0.06 ± 0.01 | 0.05 ± 0.01 | 0.30 ± 0.03 | 0.03 ± 0.01 | 6.66 ± 0.80 | 0.04 ± 0.01 | 0.29 ± 0.08 |
a
From quadruplicate experiments.